Stocktoria
Evotec SE EVT.DE
DE · Deutsche Börse Xetra · XETR · stock · Healthcare · website
Evotec SE financials (annual)
Bars are annual figures from 2022 to 2025; red bars are negative (a loss or cash outflow).
| Metric | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|
| Revenue | €788.4M | €797.0M | €781.4M | €751.4M |
| Gross profit | €114.2M | €114.9M | €175.1M | €174.1M |
| R&D expense | €37.5M | €50.9M | €68.5M | €76.6M |
| SG&A expense | €176.0M | €188.2M | €169.6M | €156.2M |
| Operating income | -€55.8M | -€78.9M | -€26.6M | €20.9M |
| Interest expense | €14.4M | €11.7M | €11.7M | €13.2M |
| Income tax | €16.8M | €2.1M | €3.3M | €21.7M |
| Net income | -€103.5M | -€196.1M | -€83.9M | -€175.7M |
| EPS (diluted) | €-0.58 | €-1.11 | €-0.47 | €-0.99 |
| Operating cash flow | -€9.2M | €18.2M | €36.4M | €205.8M |
| Free cash flow | -€91.8M | -€114.0M | -€179.6M | €24.5M |
| Cash & equivalents | €401.8M | €293.5M | €510.9M | €400.7M |
| Inventory | €29.3M | €31.1M | €30.9M | €29.8M |
| Goodwill | €272.4M | €282.9M | €275.6M | €274.8M |
| Total assets | €1.7B | €1.9B | €2.3B | €2.3B |
| Total debt | €447.7M | €443.5M | €626.2M | €506.7M |
| Total liabilities | €900.2M | €960.0M | €1.1B | €1.1B |
| Shareholders' equity | €813.7M | €952.5M | €1.1B | €1.2B |
| Share buybacks | €1.5M | €0 | €0 | — |
Growth · year-over-year · Revenue CAGR 1.6%
| Metric | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|
| Revenue growth | -1.1% | +2.0% | +4.0% | — |
| Free cash flow growth | — | — | -834.2% | — |
Each column is the change versus the prior fiscal year. Growth off a negative or zero base is shown as “—”. CAGR is the compound annual revenue growth across the years shown.
Computed from company filings · DE · as of 2025-12-31. Figures in EUR. Facts plus Stocktoria's own computed scores — not investment advice.